Retail Traders Bet on SLS, MLTX as Merck Eyes Biotech Deals Ahead of Keytruda's $31.7B Patent Cliff in 2028
According to Stocktwits sentiment data as of July 12, retail traders are actively betting on Sellas Life Sciences (SLS) and MoonLake Immunotherapeutics (MLTX) as potential acquisition targets for Merck & Co. (MRK) as the drugmaker prepares for the approaching loss of exclusivity for its flagship
GateNews·07-13 03:32



